Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.80 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4722356 | 0.89 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4724471 | 0.86 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4723191 | 0.80 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4721189 | 0.78 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4722398 | 0.77 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4720916 | 0.70 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4721128 | 0.69 | HRH3 (0.82) | SLC6A4HRH3 | |
| SCHEMBL4722875 | 0.69 | SLC6A4 (1.00) | SLC6A4HRH3 | |
| SCHEMBL4723286 | 0.69 | SLC6A4 (0.80) | SLC6A4HRH3 | |
| SCHEMBL4721192 | 0.69 | HRH3 (0.81) | SLC6A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | claimed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | claimed |
| EP-1899334-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | claimed |
| WO-2006138714-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | claimed |
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | claimed |
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | HRH3, HRH4, HRH1 | SLC6A4 10/4885HRH3 1/4885MEN1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.